DOCS NYSE
Doximity, Inc.
1W: +6.0%
1M: +6.1%
3M: +22.2%
YTD: -35.5%
1Y: -60.5%
3Y: +35.3%
5Y: -67.6%
$27.93
-0.57 (-2.00%)
Weekly Expected Move ±6.7%
$24
$26
$28
$30
$32
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#11
of 118
Medical - Healthcare Information Services
Technical Signal Map
5 Bullish
1 Neutral
6 Bearish
DOCS
$5.2B
Doximity, Inc.
BULLISH
+62
HNGE
$7.6B
Hinge Health, Inc.
BULLISH
+91
TEM
$13B
Tempus AI, Inc.
BULLISH
+82
BTSGU
$12B
BrightSpring Health Services, Inc. Tangible Equity Unit
BULLISH
+68
BTSG
$12B
BrightSpring Health Services, Inc. Common Stock
BULLISH
+51
HTFL
$4.2B
Heartflow, Inc. Common Stock
NEUTRAL
-7
WAY
$4.8B
Waystar Holding Corp.
LEAN BEAR
-11
PRVA
$2.6B
Privia Health Group, Inc.
LEAN BEAR
-15
MTHRY
$7.3B
M3, Inc.
LEAN BEAR
-29
ALBHF
$5.8B
Alibaba Health Information Technology Limited
BEARISH
-50
HQY
$7.5B
HealthEquity, Inc.
BEARISH
-78
PMCUF
$11B
Pro Medicus Limited
BEARISH
-87
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| DOCS Doximity, Inc. | $5.2B | 31.4 | 19.3 | 79.3 | 13.1 | 13.1 | 6 | BULLISH | -60.5 |
| HNGE Hinge Health, Inc. | $7.6B | 72.5 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 100.3 |
| TEM Tempus AI, Inc. | $13B | -53.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BULLISH | -12.9 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 95.6 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 101.9 |
| HTFL Heartflow, Inc. Common Stock | $4.2B | -34.7 | -42.3 | -39.8 | -24.6 | — | 2 | NEUTRAL | 37.3 |
| WAY Waystar Holding Corp. | $4.8B | 34.5 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | LEAN BEAR | -33.2 |
| PRVA Privia Health Group, Inc. | $2.6B | 90.3 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | LEAN BEAR | -18.7 |
| MTHRY M3, Inc. | $7.3B | 25.5 | 13.1 | 17.9 | 8.6 | 25.0 | 6 | LEAN BEAR | -28.7 |
| ALBHF Alibaba Health Information Technology Limited | $5.8B | 20.2 | 17.6 | 33.4 | 3.8 | 2.9 | 5 | BEARISH | -57.5 |
| HQY HealthEquity, Inc. | $7.5B | 32.2 | 10.2 | 9.0 | 14.9 | 9.5 | 9 | BEARISH | -0.7 |
| PMCUF Pro Medicus Limited | $11B | 61.6 | 119.2 | 123.5 | 68.7 | 65.7 | 5 | BEARISH | -46.2 |
| DOCS Doximity, Inc. | $5.2B | 31.4 | 19.3 | 79.3 | 13.1 | 13.1 | 6 | BULLISH | -60.5 |
| MANE Veradermics, Incorporated | $4.9B | — | — | — | — | — | — | BULLISH | — |
| CRSP CRISPR Therapeutics AG | $5.3B | -11.6 | -26.1 | -253.2 | -895.3 | -62.7 | 2 | NEUTRAL | -16.2 |
| BLLN BillionToOne, Inc. | $4.9B | 153.5 | 6.0 | 25.2 | 7.4 | — | 4 | NEUTRAL | — |
| TRSBF 3SBio Inc. | $5.4B | 4.1 | 50.1 | 99.1 | 25.3 | 66.8 | 7 | BEARISH | -38.6 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -83.2 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | BEARISH | -14.8 |
| ERAS Erasca, Inc. | $5.1B | -15.5 | -78.2 | -87.5 | — | — | 2 | BEARISH | 567.0 |
| STVN Stevanato Group S.p.A. | $5.5B | 37.4 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -23.2 |
| DFTX Definium Therapeutics, Inc. | $5.0B | -10.9 | -25.7 | 82.4 | — | — | 2 | BEARISH | — |
| GALNF Galenica AG | $4.9B | 25.5 | 25.0 | 19.2 | 3.1 | 7.5 | 5 | BEARISH | 30.6 |
| ORKA Oruka Therapeutics, Inc. | $5.1B | -34.2 | -18.2 | -50.3 | — | — | 4 | BEARISH | 353.9 |
| RDNT RadNet, Inc. | $5.5B | -262.4 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BEARISH | -10.3 |
| TFX Teleflex Incorporated | $5.5B | -5.3 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BEARISH | 0.5 |
| DNTH Dianthus Therapeutics, Inc. | $4.9B | -678.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 126.6 |
| SHC Sotera Health Company | $5.2B | 31.8 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | BEARISH | 12.5 |
| MMSI Merit Medical Systems, Inc. | $5.1B | 34.8 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BEARISH | 4.0 |
| TVTX Travere Therapeutics, Inc. | $5.3B | -126.5 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 129.7 |
| PTCT PTC Therapeutics, Inc. | $5.3B | -129.5 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | 2.3 |
| COGT Cogent Biosciences, Inc. | $5.3B | -13.4 | -109.7 | 1964.0 | — | — | 3 | BEARISH | 119.5 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.1B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 13.6 |
| MMED MiniMed Group, Inc. Common Stock | $5.5B | — | — | — | — | — | — | BEARISH | — |
| DOCS Doximity, Inc. | $5.2B | 31.4 | 19.3 | 79.3 | 13.1 | 13.1 | 6 | BULLISH | -60.5 |
| IBRX ImmunityBio, Inc. | $11B | -10.6 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BULLISH | 314.9 |
| ONTTF Oxford Nanopore Technologies plc | $3.0B | -14.0 | -52.9 | -79.5 | -41.1 | 33.0 | 3 | BULLISH | 39.5 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.2B | -14.8 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 151.6 |
| MRNA Moderna, Inc. | $75B | -23.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 668.3 |
| NTRA Natera, Inc. | $59B | -301.7 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 153.9 |
| A Agilent Technologies, Inc. | $47B | 33.0 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 21.0 |
| VTRS Viatris Inc. | $20B | -48.9 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 76.5 |
| RVTY Revvity, Inc. | $17B | 72.2 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 65.3 |
| GNNSF Genscript Biotech Corporation | $12B | -18.7 | 97.0 | 11.1 | -32.0 | -19.0 | 4 | BULLISH | 145.3 |
| TXG 10x Genomics, Inc. | $12B | -158.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BULLISH | 654.6 |
| TWST Twist Bioscience Corporation | $12B | -85.0 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BULLISH | 544.8 |
| HNGE Hinge Health, Inc. | $7.6B | 72.5 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 100.3 |
| IOVA Iovance Biotherapeutics, Inc. | $6.3B | -20.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 543.4 |
| GRAL GRAIL Inc. | $6.2B | -14.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 130.8 |
| LGND Ligand Pharmaceuticals Incorporated | $6.1B | 30.3 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 69.2 |
| KOD Kodiak Sciences Inc. | $5.9B | -22.5 | -368.4 | -630.1 | — | — | 1 | BULLISH | 499.3 |
| MANE Veradermics, Incorporated | $4.9B | — | — | — | — | — | — | BULLISH | — |
| ABCL AbCellera Biologics Inc. | $4.2B | -25.4 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BULLISH | 130.5 |
| CDNA CareDx, Inc | $3.5B | 31.2 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 347.7 |
| PGEN Precigen, Inc. | $3.0B | -7.5 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BULLISH | 155.7 |
| UFPT UFP Technologies, Inc. | $2.3B | 32.1 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | BULLISH | 50.7 |
| SBHMY Sino Biopharmaceutical Limited | $14B | 35.8 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BULLISH | -19.2 |
| INCPF InnoCare Pharma Limited | $2.8B | 22.4 | 12.6 | 127.0 | 23.1 | 108.5 | 5 | BULLISH | -43.2 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | -4.0 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -19.2 |
| WXXWY WuXi Biologics (Cayman) Inc. | $29B | 38.5 | 20.6 | 28.5 | 20.7 | 28.7 | 9 | BULLISH | 30.2 |
| TEM Tempus AI, Inc. | $13B | -53.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BULLISH | -12.9 |
| OABIW OmniAb, Inc. | $2.5B | -13.5 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -9.3 |
| ORINY Orion Oyj | $27B | 19.4 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 31.4 |
| BIO-B Bio-Rad Laboratories, Inc. | $10B | 44.3 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 29.2 |
| HYPMY Hypera S.A. | $3.4B | 9.4 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BULLISH | 20.1 |
| BVNKF Bavarian Nordic A/S | $2.6B | 11.0 | 12.2 | 13.3 | 36.0 | -2.6 | 7 | BULLISH | -7.3 |
| DHR Danaher Corporation | $150B | 37.9 | 7.6 | 5.8 | 13.9 | 4.6 | 6 | BULLISH | 0.6 |
| RGEN Repligen Corporation | $10B | 245.5 | 2.0 | 2.6 | 2.5 | 16.5 | 8 | BULLISH | 24.6 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $10B | 19.9 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BULLISH | 3.2 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 95.6 |
| MTD Mettler-Toledo International Inc. | $30B | 33.4 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 15.3 |
| CSPCY CSPC Pharmaceutical Group Limited | $15B | 13.1 | 25.6 | 43.2 | 32.8 | 0.7 | 6 | BULLISH | 8.3 |
| BRKR Bruker Corporation | $9.6B | -90.5 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 82.3 |
| RMYHY Ramsay Health Care Limited | $8.9B | 40.0 | 7.2 | 12.3 | 1.8 | 14.8 | 5 | BULLISH | 76.2 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 40.8 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 95.6 |
| ANSLY Ansell Limited | $4.4B | 21.2 | 16.0 | 14.8 | 10.8 | 27.0 | 7 | BULLISH | 37.5 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 22.9 |
| VCYT Veracyte, Inc. | $3.7B | 31.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 26.5 |
| CZMWF Carl Zeiss Meditec AG | $3.3B | 18.7 | 5.6 | 4.8 | 9.8 | 47.0 | 7 | BULLISH | -23.0 |
| BFLY Butterfly Network, Inc. | $2.4B | -30.9 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | BULLISH | 370.0 |
| ALMR Alamar Biosciences, Inc. | $2.4B | — | — | — | — | — | — | BULLISH | — |
| TCNNF Trulieve Cannabis Corp. | $2.4B | -26.5 | -47.6 | -20.5 | -149.8 | -3.9 | 5 | BULLISH | 37.6 |
| SSMXF Sysmex Corporation | $7.5B | 28.5 | 7.3 | 9.3 | 1.3 | -1.1 | 5 | BULLISH | 2.9 |
| RCDTF Recordati S.p.A. | $12B | 21.6 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.3 | 11.8 | 10.2 | 3.2 | 8.7 | 6 | BULLISH | -12.2 |
| RGC Regencell Bioscience Holdings Limited | $3.4B | -480.3 | -156.4 | 957.8 | — | 100.0 | 2 | BULLISH | -56.9 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 63.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 97.1 |
| WAT Waters Corporation | $42B | 105.8 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 33.0 |
| GH Guardant Health, Inc. | $24B | -50.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 183.8 |
| GNMSF Genmab A/S | $22B | 26.5 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 15.3 |
| SONVY Sonova Holding AG | $18B | 34.4 | 38.1 | 33.3 | 13.5 | 1.0 | 7 | BULLISH | 10.2 |
| CON Concentra Group Holdings Parent, Inc. | $4.6B | 23.0 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 71.6 |
| ADPT Adaptive Biotechnologies Corporation | $4.5B | -69.6 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BULLISH | 94.7 |
| UTHR United Therapeutics Corporation | $23B | 17.9 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 23.6 |
| SUVPF Sartorius AG | $19B | 88.8 | 7.2 | 6.7 | 7.2 | 3.4 | 8 | BULLISH | 24.7 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $6.5B | 18.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BULLISH | -30.0 |
| SGFEF Siegfried Holding AG | $3.9B | 17.9 | 34.3 | 18.4 | 10.8 | 3.9 | 6 | BULLISH | -22.9 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.5 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | BULLISH | -4.5 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 101.9 |
| EXEL Exelixis, Inc. | $15B | 17.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 41.7 |
| ADMA ADMA Biologics, Inc. | $2.2B | 13.5 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -35.4 |
| QGEN Qiagen N.V. | $9.2B | 22.9 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | -3.4 |
| SNPHF Santen Pharmaceutical Co., Ltd. | $4.2B | 13.8 | 12.8 | 14.4 | 19.2 | -2.3 | 7 | BULLISH | 14.0 |
| RVMDW Revolution Medicines, Inc. Warrant | $45B | -23.3 | -79.1 | 186.4 | — | — | 1 | BULLISH | 3872.4 |
| RVMD Revolution Medicines, Inc. | $44B | -23.3 | -79.1 | 186.4 | — | — | 1 | BULLISH | 350.6 |
| BMXXY bioMérieux S.A. | $11B | 19.5 | 20.5 | 18.1 | 11.5 | 45.2 | 9 | BULLISH | -38.2 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.8 | 1.9 | 8.4 | 6.6 | -8.6 | 7 | BULLISH | 84.1 |
| ISRG Intuitive Surgical, Inc. | $138B | 44.3 | 17.4 | 22.1 | 28.3 | 20.7 | 7 | BULLISH | -10.5 |
| CLCGY Clicks Group Limited | $3.0B | 14.9 | 109.2 | 70.8 | 5.7 | 14.5 | 9 | BULLISH | -37.3 |
| ILMN Illumina, Inc. | $41B | 50.5 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 167.0 |
| MAHLY MediPal Holdings Corporation | $3.9B | 12.9 | 6.8 | 9.6 | 0.6 | 5.4 | 7 | BULLISH | 4.5 |
| WILYY Demant A/S | $9.9B | 40.7 | 38.1 | 21.5 | 9.1 | 8.7 | 5 | BULLISH | 27.3 |
| BRCTF BioArctic AB (publ) | $3.3B | 256.5 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BULLISH | 17.6 |
| SYRE Spyre Therapeutics, Inc. | $8.1B | -47.8 | -23.0 | 359.8 | — | — | 3 | BULLISH | 466.2 |
| IVBXF Innovent Biologics, Inc. | $22B | 116.2 | 14.2 | 93.7 | 14.5 | 115.6 | 8 | BULLISH | 4.7 |
| HIMS Hims & Hers Health, Inc. | $6.5B | -47.5 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BULLISH | -48.5 |
| TKPHF Takeda Pharmaceutical Company Limited | $59B | 49.4 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 26.8 |
| WST West Pharmaceutical Services, Inc. | $26B | 46.4 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.6 |
| TCHBF Tecan Group AG | $3.4B | -25.2 | -4.2 | 8.0 | 2.9 | -15.6 | 4 | BULLISH | 35.5 |
| HAE Haemonetics Corporation | $4.8B | 50.8 | 12.0 | 10.4 | -5.8 | -2.0 | 6 | BULLISH | 114.5 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | BULLISH | 25.3 |
| HCM HUTCHMED (China) Limited | $2.5B | 155.0 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -11.0 |
| INSP Inspire Medical Systems, Inc. | $2.0B | 15.0 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | BULLISH | -3.3 |
| MKGAF Merck KGaA | $68B | 25.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 9.2 |
| LZAGY Lonza Group AG | $49B | -367.3 | 21.3 | 17.9 | 17.5 | 3.7 | 7 | LEAN BULL | -0.1 |
| MDLN Medline Inc. | $30B | 41.4 | 3.2 | 4.4 | 0.8 | — | 4 | LEAN BULL | — |
| RADLY Raia Drogasil S.A. | $6.6B | 25.1 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | LEAN BULL | 11.9 |
| DSKYF Daiichi Sankyo Company, Limited | $34B | 20.5 | 15.8 | 13.5 | 7.2 | 13.2 | 4 | LEAN BULL | -18.6 |
| NHC National HealthCare Corporation | $3.6B | 25.2 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | LEAN BULL | 82.7 |
| ERFSF Eurofins Scientific SE | $15B | 25.0 | 21.7 | 11.3 | 8.2 | 9.7 | 6 | LEAN BULL | 19.6 |
| SZUKF Suzuken Co., Ltd. | $2.0B | 9.4 | 9.3 | 9.3 | 1.2 | 4.2 | 3 | LEAN BULL | 4.8 |
| HOCPY HOYA Corporation | $52B | 30.6 | 25.7 | 51.3 | 21.9 | 10.7 | 5 | LEAN BULL | 9.7 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $15B | 57.5 | 51.3 | 21.1 | 20.6 | 36.8 | 9 | LEAN BULL | 24.9 |
| CRL Charles River Laboratories International, Inc. | $14B | -60.0 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | LEAN BULL | 70.2 |
| CSLLY CSL Limited | $118B | -23.1 | 2.8 | 26.7 | -40.2 | 10.2 | 5 | LEAN BULL | -5.4 |
| SMDPY Sumitomo Pharma Co., Ltd. | $4.6B | 5.8 | 46.9 | 11.7 | -0.8 | 15.2 | 5 | LEAN BULL | -6.1 |
| CNVVF ConvaTec Group Plc | $5.7B | 45.2 | 21.9 | 19.2 | 4.4 | 10.0 | 6 | LEAN BULL | 0.3 |
| WUXIF WuXi AppTec Co., Ltd. | $80B | 22.1 | 30.2 | 35.1 | 38.9 | 24.9 | 6 | LEAN BULL | 91.1 |
| CORT Corcept Therapeutics Incorporated | $13B | 223.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | LEAN BULL | 38.0 |
| GNNDY GN Store Nord A/S | $2.3B | -27.4 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | LEAN BULL | -6.1 |
| AVTR Avantor, Inc. | $10B | -18.3 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | LEAN BULL | 12.2 |
| NHNKY Nihon Kohden Corporation | $3.2B | 18.7 | 8.1 | 8.7 | 11.4 | 5.2 | 8 | LEAN BULL | -17.1 |
| AMBBY Ambu A/S | $2.9B | 35.3 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | LEAN BULL | -25.9 |
| MEDP Medpace Holdings, Inc. | $17B | 34.5 | 162.2 | 933.8 | 17.2 | 24.7 | 8 | LEAN BULL | 10.2 |
| VCEL Vericel Corporation | $2.1B | 83.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | LEAN BULL | 29.9 |
| PFE Pfizer Inc. | $158B | 36.7 | 5.0 | 12.1 | -1.6 | -0.2 | 7 | NEUTRAL | 3.9 |
| RDY Dr. Reddy's Laboratories Limited | $10B | 30.4 | 12.2 | 10.7 | 2.9 | 3.6 | 3 | NEUTRAL | -13.7 |
| CRSP CRISPR Therapeutics AG | $5.3B | -11.6 | -26.1 | -253.2 | -895.3 | -62.7 | 2 | NEUTRAL | -16.2 |
| CAI Caris Life Sciences, Inc. | $8.0B | 76.1 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | NEUTRAL | -6.7 |
| ESALF Eisai Co., Ltd. | $8.6B | 31.3 | 3.7 | 3.2 | 7.8 | 242.3 | 6 | NEUTRAL | -11.6 |
| TECH Bio-Techne Corporation | $11B | 61.9 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | NEUTRAL | 21.0 |
| AAVXF Abivax S.A. | $10B | -17.7 | -222.4 | 781.9 | — | -70.4 | 3 | NEUTRAL | 61.4 |
| BCHMF Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.5 | 15.4 | 24.3 | 6 | NEUTRAL | 48.1 |
| HLUBF H. Lundbeck A/S | $6.8B | 11.2 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | NEUTRAL | 17.0 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 27.3 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 16.4 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 19.9 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| CHSYF China Medical System Holdings Limited | $3.8B | 14.6 | 18.7 | 19.8 | 21.9 | 0.7 | 5 | NEUTRAL | 16.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.6 | 11.4 | 3.2 | 93.0 | 8.4 | 6 | NEUTRAL | 5.3 |
| ARSUF Fagron N.V. | $2.0B | 18.0 | 33.2 | 20.7 | 8.4 | 25.8 | 5 | NEUTRAL | 17.0 |
| HCA HCA Healthcare, Inc. | $92B | 14.2 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.3 |
| SMMT Summit Therapeutics Inc. | $13B | -15.0 | -192.5 | 1714.4 | — | — | 3 | NEUTRAL | -18.2 |
| OPHLF Ono Pharmaceutical Co., Ltd. | $7.0B | 14.1 | 8.6 | 10.5 | 0.7 | 6.5 | 7 | NEUTRAL | 44.4 |
| INDV Indivior Pharmaceuticals Inc | $4.5B | 12.6 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | NEUTRAL | 52.2 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 16.0 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 56.8 |
| BLLN BillionToOne, Inc. | $4.9B | 153.5 | 6.0 | 25.2 | 7.4 | — | 4 | NEUTRAL | — |
| ESLOF EssilorLuxottica S.A. | $78B | 26.4 | 12.5 | 10.2 | 10.6 | 10.4 | 7 | NEUTRAL | -48.6 |
| HTFL Heartflow, Inc. Common Stock | $4.2B | -34.7 | -42.3 | -39.8 | -24.6 | — | 2 | NEUTRAL | 37.3 |
| SHPMF Shanghai Pharmaceuticals Holding Co., Ltd | $8.5B | 12.6 | 6.2 | 6.5 | 2.9 | 4.0 | 5 | NEUTRAL | -4.6 |
| HALO Halozyme Therapeutics, Inc. | $13B | 31.2 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | NEUTRAL | 46.6 |
| ALVOW Alvotech | $2.4B | -9.3 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | NEUTRAL | -81.7 |
| SOAGY Sartorius AG ADR | $83B | 88.8 | 7.2 | 6.5 | 7.2 | 3.4 | 7 | LEAN BEAR | 10.9 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | LEAN BEAR | -13.6 |
| WAY Waystar Holding Corp. | $4.8B | 34.5 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | LEAN BEAR | -33.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.1B | 113.9 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | LEAN BEAR | 27.3 |
| GIKLY Grifols, S.A. | $15B | 14.2 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | LEAN BEAR | -20.0 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 17.4 | 12.3 | 19.3 | 16.7 | -9.6 | 4 | LEAN BEAR | 0.0 |
| PRVA Privia Health Group, Inc. | $2.6B | 90.3 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | LEAN BEAR | -18.7 |
| MCK McKesson Corporation | $106B | 24.0 | -224.3 | 212.4 | 1.7 | 12.4 | 7 | LEAN BEAR | 18.1 |
| PACS PACS Group, Inc. | $6.8B | 25.2 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | LEAN BEAR | 205.7 |
| ATRC AtriCure, Inc. | $2.8B | 259.8 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | LEAN BEAR | 61.1 |
| MD Pediatrix Medical Group, Inc. | $2.1B | 12.3 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | LEAN BEAR | 52.9 |
| ONC BeOne Medicines AG | $38B | 26.3 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | LEAN BEAR | 6.8 |
| OSCR Oscar Health, Inc. | $8.0B | 18.1 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BEAR | 63.7 |
| BIIB Biogen Inc. | $32B | 38.7 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | LEAN BEAR | 42.6 |
| TGTX TG Therapeutics, Inc. | $8.3B | 17.8 | 100.3 | 73.5 | 3.2 | 76.1 | 5 | LEAN BEAR | 48.5 |
| KYKOF Kyowa Kirin Co., Ltd. | $7.3B | 14.4 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | LEAN BEAR | -18.0 |
| TNGX Tango Therapeutics, Inc. | $3.8B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | LEAN BEAR | 191.2 |
| CLOV Clover Health Investments, Corp. | $2.3B | -108.1 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | LEAN BEAR | 67.2 |
| TRUMY Terumo Corporation | $21B | 20.1 | 9.3 | 8.5 | 8.8 | 10.7 | 4 | LEAN BEAR | -14.0 |
| COO The Cooper Companies, Inc. | $11B | 19.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | LEAN BEAR | -16.4 |
| RLAY Relay Therapeutics, Inc. | $4.2B | -12.1 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 256.4 |
| DXCM DexCom, Inc. | $32B | 33.0 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | LEAN BEAR | 29.2 |
| HUM Humana Inc. | $47B | 36.5 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | LEAN BEAR | 57.4 |
| VKTX Viking Therapeutics, Inc. | $3.5B | -6.4 | -88.9 | 495.6 | — | — | 1 | LEAN BEAR | 9.4 |
| GRDN Guardian Pharmacy Services, Inc. | $2.7B | 40.4 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | LEAN BEAR | 74.1 |
| OCPNF Olympus Corporation | $13B | 27.5 | 8.7 | 11.6 | 8.4 | 1.5 | 6 | LEAN BEAR | -2.3 |
| FMCQF Fresenius Medical Care AG | $12B | 11.9 | 7.3 | 7.0 | 4.5 | -0.4 | 7 | LEAN BEAR | -13.1 |
| CURLF Curaleaf Holdings, Inc. | $2.6B | -72.5 | -4.2 | 0.5 | 3.7 | 2.4 | 7 | LEAN BEAR | 14.0 |
| SAUHF Straumann Holding AG | $18B | 38.5 | 36.0 | 38.6 | 18.2 | 7.9 | 6 | LEAN BEAR | 3.4 |
| MTHRY M3, Inc. | $7.3B | 25.5 | 13.1 | 17.9 | 8.6 | 25.0 | 6 | LEAN BEAR | -28.7 |
| GMED Globus Medical, Inc. | $10B | 19.0 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BEARISH | 28.8 |
| HLNCF Haleon plc | $39B | 18.1 | 9.4 | 7.3 | 14.7 | -2.1 | 7 | BEARISH | 2.1 |
| NEOG Neogen Corporation | $2.6B | -366.0 | -0.4 | -0.6 | -5.0 | -2.7 | 6 | BEARISH | 109.5 |
| BHC Bausch Health Companies Inc. | $2.2B | -2.0 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BEARISH | -12.2 |
| RSMDF ResMed Inc. | $44B | 21.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -14.5 |
| SDZNY Sandoz Group AG | $36B | 55.5 | 9.3 | 17.9 | 1.9 | 134.6 | 5 | BEARISH | 47.5 |
| ALPMF Astellas Pharma Inc. | $26B | 11.0 | 17.5 | 14.8 | 8.1 | 12.5 | 8 | BEARISH | 29.5 |
| SLS SELLAS Life Sciences Group, Inc. | $2.2B | -55.6 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 594.7 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 730.0 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | BEARISH | 11.2 |
| MCVEF Medicover AB (publ) | $4.1B | 40.2 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | BEARISH | 0.0 |
| IDXX IDEXX Laboratories, Inc. | $41B | 36.4 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BEARISH | -16.4 |
| TRSBF 3SBio Inc. | $5.4B | 4.1 | 50.1 | 99.1 | 25.3 | 66.8 | 7 | BEARISH | -38.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.3B | 12.7 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 47.2 |
| SGIOY Shionogi & Co., Ltd. | $15B | 9.0 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BEARISH | 1.5 |
| PBLS Parabilis Medicines, Inc. | $3.5B | — | — | — | — | — | — | BEARISH | — |
| BAX Baxter International Inc. | $12B | -11.5 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BEARISH | 0.6 |
| DVA DaVita Inc. | $11B | 15.4 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BEARISH | 34.5 |
| GKOS Glaukos Corporation | $9.7B | -50.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BEARISH | 96.9 |
| HKMPY Hikma Pharmaceuticals PLC | $4.5B | 11.7 | 31.4 | 21.7 | 12.9 | 14.3 | 7 | BEARISH | -7.1 |
| MBX MBX Biosciences, Inc. Common Stock | $2.8B | -24.4 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 226.9 |
| PCVX Vaxcyte, Inc. | $8.2B | -7.4 | -36.5 | -66.4 | — | — | 0 | BEARISH | 48.5 |
| GNGBY Getinge AB (publ) | $6.7B | 25.1 | 8.9 | 8.0 | 10.0 | -3.9 | 8 | BEARISH | 11.1 |
| ZLAB Zai Lab Limited | $2.8B | -14.4 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | BEARISH | -29.4 |
| NAMSW NewAmsterdam Pharma Company N.V. | $2.7B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -26.1 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -83.2 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | BEARISH | -14.8 |
| BAYRY Bayer AG | $50B | -25.5 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 45.3 |
| SEMHF Siemens Healthineers AG | $49B | 19.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BEARISH | -21.2 |
| JAZZ Jazz Pharmaceuticals plc | $15B | 15.5 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 72.2 |
| ALBHF Alibaba Health Information Technology Limited | $5.8B | 20.2 | 17.6 | 33.4 | 3.8 | 2.9 | 5 | BEARISH | -57.5 |
| ERAS Erasca, Inc. | $5.1B | -15.5 | -78.2 | -87.5 | — | — | 2 | BEARISH | 567.0 |
| ICUI ICU Medical, Inc. | $4.0B | 132.8 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BEARISH | 31.8 |
| GILD Gilead Sciences, Inc. | $179B | -55.7 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BEARISH | 31.1 |
| IQV IQVIA Holdings Inc. | $42B | 31.8 | 23.0 | 9.6 | 5.9 | 8.2 | 7 | BEARISH | 26.7 |
| PTKFF PT Kalbe Farma Tbk. | $2.4B | 9.1 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | BEARISH | -16.3 |
| ULIHF The United Laboratories International Holdings Limited | $2.1B | 23.4 | 23.4 | 27.9 | 5.6 | -4.4 | 4 | BEARISH | -52.6 |
| IPSEY Ipsen S.A. | $55B | 22.5 | 21.9 | 29.9 | 17.5 | 22.1 | 6 | BEARISH | 26.2 |
| CAH Cardinal Health, Inc. | $53B | 31.4 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BEARISH | 44.5 |
| UCBJF UCB S.A. | $45B | 17.7 | 34.2 | 26.5 | 26.0 | 44.5 | 8 | BEARISH | -18.9 |
| GEHC GE HealthCare Technologies Inc. | $29B | 18.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BEARISH | -14.8 |
| BEAM Beam Therapeutics Inc. | $2.5B | -29.9 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | 1.5 |
| EW Edwards Lifesciences Corporation | $49B | 48.9 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BEARISH | 11.6 |
| BNTX BioNTech SE | $24B | -12.7 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -5.2 |
| SOLV Solventum Corporation | $15B | 10.7 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 20.3 |
| ICLR ICON Public Limited Company | $12B | 37.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BEARISH | -15.7 |
| RGEDF Gedeon Richter PLC | $7.0B | 9.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BEARISH | 32.3 |
| KNSA Kiniksa Pharmaceuticals International, plc | $5.8B | 70.8 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 96.1 |
| STVN Stevanato Group S.p.A. | $5.5B | 37.4 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -23.2 |
| BBIO BridgeBio Pharma, Inc. | $13B | -18.8 | 32.4 | 57.9 | -68.4 | 193.4 | 4 | BEARISH | 25.8 |
| SKHCF Sonic Healthcare Limited | $6.4B | 15.0 | 13.8 | 22.2 | 6.2 | 21.4 | 5 | BEARISH | -12.3 |
| DGX Quest Diagnostics Incorporated | $26B | 24.4 | 14.4 | 9.5 | 10.5 | 9.9 | 8 | BEARISH | 28.7 |
| RPRX Royalty Pharma plc | $25B | 23.7 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BEARISH | 58.2 |
| DFTX Definium Therapeutics, Inc. | $5.0B | -10.9 | -25.7 | 82.4 | — | — | 2 | BEARISH | — |
| LQDA Liquidia Corporation | $2.5B | 18.3 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BEARISH | 29.9 |
| LEGN Legend Biotech Corporation | $3.4B | -37.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BEARISH | -43.1 |
| THC Tenet Healthcare Corporation | $21B | 9.9 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 28.4 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 11.9 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | BEARISH | -16.4 |
| HSIC Henry Schein, Inc. | $9.7B | 24.5 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 29.4 |
| PODD Insulet Corp. | $9.1B | 24.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BEARISH | -57.0 |
| CHE Chemed Corporation | $6.6B | 25.5 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BEARISH | 15.3 |
| BLCO Bausch + Lomb Corporation | $6.1B | -35.8 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BEARISH | 16.6 |
| GALNF Galenica AG | $4.9B | 25.5 | 25.0 | 19.2 | 3.1 | 7.5 | 5 | BEARISH | 30.6 |
| ROIV Roivant Sciences Ltd. | $26B | -94.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BEARISH | 126.8 |
| EHC Encompass Health Corporation | $12B | 19.3 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.8 |
| TLPPF Telix Pharmaceuticals Limited | $3.6B | 109.7 | 14.8 | 5.8 | 8.0 | 201.7 | 5 | BEARISH | 15.3 |
| IDYA IDEAYA Biosciences, Inc. | $3.5B | -19.5 | -16.2 | -42.9 | -1269.6 | 3244.7 | 3 | BEARISH | 36.5 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.0B | 6.7 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BEARISH | 38.9 |
| NVST Envista Holdings Corp | $3.8B | 39.8 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | BEARISH | 15.3 |
| DNLI Denali Therapeutics Inc. | $3.2B | -7.0 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 34.1 |
| PLSE Pulse Biosciences, Inc. | $3.3B | -40.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BEARISH | 164.3 |
| FSNUY Fresenius SE & Co. KGaA | $112B | 15.9 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BEARISH | -11.5 |
| ELV Elevance Health Inc. | $84B | 17.2 | 11.2 | 15.5 | 2.9 | 6.3 | 6 | BEARISH | 16.8 |
| REGN Regeneron Pharmaceuticals, Inc. | $76B | 17.6 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BEARISH | 22.7 |
| CNC Centene Corp. | $31B | -6.1 | -20.4 | -37.1 | 2.5 | 8.7 | 6 | BEARISH | 76.2 |
| LH Labcorp Holdings Inc. | $25B | 25.3 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BEARISH | 10.9 |
| MOH Molina Healthcare, Inc. | $9.9B | 1184.6 | -0.2 | -29.6 | 0.6 | 2.6 | 6 | BEARISH | -1.7 |
| IMVT Immunovant, Inc. | $6.9B | -11.9 | -64.8 | 851.4 | — | — | 2 | BEARISH | 105.8 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.7 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 93.6 |
| CGON CG Oncology Inc. | $5.9B | -25.0 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 70.8 |
| RDNT RadNet, Inc. | $5.5B | -262.4 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BEARISH | -10.3 |
| ORKA Oruka Therapeutics, Inc. | $5.1B | -34.2 | -18.2 | -50.3 | — | — | 4 | BEARISH | 353.9 |
| LFST LifeStance Health Group, Inc. | $4.6B | 90.9 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BEARISH | 117.1 |
| EWTX Edgewise Therapeutics, Inc. | $4.5B | -22.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 168.1 |
| RCUS Arcus Biosciences, Inc. | $3.1B | -6.2 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 81.5 |
| TMDX TransMedics Group, Inc. | $2.8B | 18.1 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -30.5 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.5 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| CLDX Celldex Therapeutics, Inc. | $2.1B | -7.3 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 25.1 |
| URGN UroGen Pharma Ltd. | $2.0B | -20.9 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 132.3 |
| NBIX Neurocrine Biosciences, Inc. | $14B | 20.3 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BEARISH | 4.5 |
| ASND Ascendis Pharma A/S | $14B | 16.7 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BEARISH | 11.6 |
| PRAX Praxis Precision Medicines, Inc. | $8.2B | -22.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 457.4 |
| CYTK Cytokinetics, Incorporated | $8.2B | -9.1 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 17.5 |
| HQY HealthEquity, Inc. | $7.5B | 32.2 | 10.2 | 9.0 | 14.9 | 9.5 | 9 | BEARISH | -0.7 |
| ALKS Alkermes plc | $7.0B | 103.6 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BEARISH | 36.2 |
| SRRK Scholar Rock Holding Corporation | $5.6B | -14.1 | -167.8 | 931.3 | — | — | 2 | BEARISH | 35.0 |
| TFX Teleflex Incorporated | $5.5B | -5.3 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BEARISH | 0.5 |
| DNTH Dianthus Therapeutics, Inc. | $4.9B | -678.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 126.6 |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | -8.0 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -2.8 |
| ELVN Enliven Therapeutics, Inc. | $3.4B | -28.6 | -15.3 | -6535.0 | — | — | 3 | BEARISH | 136.9 |
| VRBCF Virbac S.A. | $3.2B | 16.6 | 26.1 | 25.2 | 11.4 | 14.6 | 7 | BEARISH | 10.8 |
| ALFRY Alfresa Holdings Corporation | $2.5B | 10.3 | 8.6 | 7.0 | 1.3 | 6.3 | 7 | BEARISH | -16.7 |
| ORPEF emeis Société anonyme | $2.3B | -4.5 | -38.4 | 2.8 | -5.4 | 2.2 | 5 | BEARISH | 0.0 |
| SYK Stryker Corporation | $106B | 28.3 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BEARISH | -24.4 |
| COR Cencora, Inc. | $60B | 22.9 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BEARISH | -0.7 |
| AKBLF ALK-Abelló A/S | $6.2B | 33.0 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BEARISH | 7.1 |
| SHTDF Sinopharm Group Co. Ltd. | $5.8B | 5.6 | 17.2 | 15.0 | 1.2 | 9.8 | 6 | BEARISH | -16.9 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.5B | -22.1 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -11.8 |
| VRTX Vertex Pharmaceuticals Incorporated | $128B | 29.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BEARISH | 24.8 |
| BMY Bristol-Myers Squibb Company | $125B | 13.5 | 46.7 | 17.9 | 25.6 | 3.1 | 8 | BEARISH | 30.7 |
| MDT Medtronic plc | $111B | 21.1 | 9.8 | 7.5 | 12.7 | 8.4 | 8 | BEARISH | -8.9 |
| BDX Becton, Dickinson and Company | $49B | 53.3 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BEARISH | -6.9 |
| INCY Incyte Corporation | $23B | 14.2 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 33.0 |
| ZBH Zimmer Biomet Holdings, Inc. | $17B | 21.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BEARISH | -10.7 |
| MDGL Madrigal Pharmaceuticals, Inc. | $12B | -38.7 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 11.2 |
| KRYS Krystal Biotech, Inc. | $9.5B | 39.0 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 79.4 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.0 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | BEARISH | 118.8 |
| KYMR Kymera Therapeutics, Inc. | $8.8B | -33.0 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BEARISH | 96.5 |
| BLTE Belite Bio, Inc | $6.4B | -57.8 | -20.8 | -11.5 | — | — | 3 | BEARISH | 117.1 |
| SHC Sotera Health Company | $5.2B | 31.8 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | BEARISH | 12.5 |
| MMSI Merit Medical Systems, Inc. | $5.1B | 34.8 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BEARISH | 4.0 |
| LIVN LivaNova PLC | $4.1B | 21.8 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BEARISH | 48.3 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.1B | -67.0 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 27.3 |
| ACHC Acadia Healthcare Company, Inc. | $2.6B | -2.3 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BEARISH | 14.3 |
| NRIX Nurix Therapeutics, Inc. | $2.4B | -6.7 | -80.3 | -1655.0 | -990.1 | -58.4 | 2 | BEARISH | 144.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.3 | -70.7 | 860.9 | — | — | 4 | BEARISH | 29.6 |
| BCRX BioCryst Pharmaceuticals, Inc. | $2.1B | -5.7 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 10.8 |
| ADUS Addus HomeCare Corporation | $2.1B | 19.6 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BEARISH | -4.0 |
| AXGN AxoGen, Inc. | $2.0B | -55.4 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | BEARISH | 109.2 |
| ABT Abbott Laboratories | $169B | 31.4 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BEARISH | -26.6 |
| CVS CVS Health Corp. | $110B | 22.6 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BEARISH | 13.4 |
| ARGNF argenx SE | $58B | 33.3 | 44.4 | 70.5 | 29.8 | 225.2 | 6 | BEARISH | 17.0 |
| OTSKF Otsuka Holdings Co., Ltd. | $38B | 14.7 | 13.7 | 12.0 | 16.7 | 9.5 | 8 | BEARISH | 27.5 |
| IHHHF IHH Healthcare Berhad | $15B | 30.7 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | BEARISH | 49.1 |
| BIOVF Swedish Orphan Biovitrum AB (publ) | $15B | 107.8 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | BEARISH | 42.8 |
| PMCUF Pro Medicus Limited | $11B | 61.6 | 119.2 | 123.5 | 68.7 | 65.7 | 5 | BEARISH | -46.2 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 150.5 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 4.2 |
| AXSM Axsome Therapeutics, Inc. | $9.2B | -47.8 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 51.2 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $9.0B | -28.7 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 83.3 |
| ATR AptarGroup, Inc. | $7.7B | 21.4 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BEARISH | -10.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.4B | -29.8 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -7.2 |
| YPHDF Ypsomed Holding AG | $5.7B | 21.9 | 40.4 | 23.5 | 22.5 | 51.4 | 8 | BEARISH | -8.1 |
| REGMF RemeGen Co., Ltd. | $5.6B | 11.3 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | 96.8 |
| TVTX Travere Therapeutics, Inc. | $5.3B | -126.5 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 129.7 |
| DSRLF DiaSorin S.p.A. | $4.2B | 23.3 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BEARISH | -10.9 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 8.9 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -6.1 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.1B | -19.7 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 98.5 |
| DYN Dyne Therapeutics, Inc. | $2.8B | -4.6 | -81.6 | 240.4 | — | — | 2 | BEARISH | 21.6 |
| MEDGF Medacta Group S.A. | $2.7B | 31.2 | 41.7 | 21.5 | 11.4 | 31.6 | 5 | BEARISH | 63.9 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.7B | 9.5 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BEARISH | 40.2 |
| IRON Disc Medicine, Inc. | $2.5B | -9.8 | -39.1 | 1672.3 | — | — | 1 | BEARISH | -3.8 |
| WGS GeneDx Holdings Corp. | $2.2B | -20.1 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -35.6 |
| INSM Insmed Incorporated | $24B | -27.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -24.6 |
| STE STERIS plc | $20B | 25.4 | 11.3 | 9.4 | 13.9 | 8.7 | 9 | BEARISH | -13.4 |
| JDHIY JD Health International Inc. | $15B | 15.4 | 19.1 | 49.0 | 8.4 | 31.9 | 6 | BEARISH | -49.5 |
| ALGN Align Technology, Inc. | $10B | 25.0 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BEARISH | 12.7 |
| CHEOF Cochlear Limited | $6.1B | 55.7 | 30.0 | 34.3 | -1.2 | 11.5 | 6 | BEARISH | -47.4 |
| PTCT PTC Therapeutics, Inc. | $5.3B | -129.5 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | 2.3 |
| CAMRF Camurus AB | $3.7B | 53.4 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| IRTC iRhythm Technologies, Inc. | $3.6B | -256.7 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BEARISH | -34.1 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 15.9 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| OPCH Option Care Health, Inc. | $3.4B | 17.0 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BEARISH | -16.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 39.7 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -30.4 |
| ZLDPF Zealand Pharma A/S | $2.8B | 6.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -47.9 |
| BKD Brookdale Senior Living Inc. | $2.6B | -18.8 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 27.0 |
| VERA Vera Therapeutics, Inc. | $2.2B | -5.2 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 5.7 |
| PBH Prestige Consumer Healthcare Inc. | $2.1B | 12.6 | 10.2 | 8.0 | 19.1 | -4.3 | 5 | BEARISH | -28.5 |
| NVO Novo Nordisk A/S | $166B | 9.5 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | BEARISH | -37.0 |
| SNY Sanofi | $96B | 21.7 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BEARISH | -19.8 |
| GSK GSK plc | $94B | 14.8 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BEARISH | 4.3 |
| CI Cigna Corporation | $71B | 11.2 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BEARISH | -6.7 |
| BSX Boston Scientific Corporation | $63B | 17.2 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BEARISH | -55.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $63B | 21.1 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BEARISH | -13.9 |
| ALC Alcon Inc. | $31B | 49.0 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BEARISH | -15.1 |
| ALNY Alnylam Pharmaceuticals, Inc. | $29B | 36.0 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -52.3 |
| ZTS Zoetis Inc. | $29B | 11.5 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BEARISH | -52.4 |
| PHG Koninklijke Philips N.V. | $23B | 18.2 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BEARISH | -13.4 |
| CLPBY Coloplast A/S | $14B | 33.6 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BEARISH | -28.4 |
| PEN Penumbra, Inc. | $13B | 77.6 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BEARISH | 27.2 |
| SNN Smith & Nephew plc | $11B | 17.2 | 21.7 | 17.4 | 9.8 | 11.5 | 8 | BEARISH | -27.6 |
| ELAN Elanco Animal Health Incorporated | $11B | -54.0 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 6.5 |
| ENSG The Ensign Group, Inc. | $10B | 26.1 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -1.5 |
| IONS Ionis Pharmaceuticals, Inc. | $7.2B | -12.6 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -33.8 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 16.7 | 10.5 | 12.8 | 4.7 | 5.8 | 5 | BEARISH | inf |
| MMED MiniMed Group, Inc. Common Stock | $5.5B | — | — | — | — | — | — | BEARISH | — |
| COGT Cogent Biosciences, Inc. | $5.3B | -13.4 | -109.7 | 1964.0 | — | — | 3 | BEARISH | 119.5 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.1B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 13.6 |
| CELC Celcuity Inc. | $3.5B | -16.8 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | 59.4 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.3 | 11.3 | 10.9 | 3.5 | 5.6 | 5 | BEARISH | inf |
| VCRE Vicore Pharma Holding AB | $2.6B | — | — | — | — | — | — | BEARISH | — |
| VRDN Viridian Therapeutics, Inc. | $2.2B | -5.5 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BEARISH | -8.8 |
| MLYS Mineralys Therapeutics, Inc. | $2.1B | -5.6 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -40.6 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
DOCS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F